Background & objectives: AmpC β-lactamases which are often plasmid mediated hydrolyze all β-lactam antibiotics except cefepime and carbapenems. We evaluated the presence of AmpC β-lactamases among Enterobacteriaceae strains recovered prospectively from patients at five Indian tertiary care centres.
AmpC β-lactamases are clinically important cephalosporinases produced by many Enterobacteriaceae strains and mediate resistance to cephalothin, cefazolin, cefoxitin, most penicillins and β-lactam/β-lactam inhibitor combinations 1 . Plasmid-mediated AmpC genes first reported in 1988, constitute an emerging therapeutic problem 2 . The plasmid-mediated AmpC genes are derived from inducible chromosomal genes that have become mobilized. Commonly reported genotypes are ACC, FOX, MOX, DHA, CIT and EBC [3] [4] [5] . These enzymes confer a resistance pattern similar to the overproduction of chromosomal AmpC β-lactamases, which may involve all β-lactam antibiotics except for carbapenems and cefepime 6 . In many bacteria, AmpC enzymes are inducible and can be expressed at high levels by mutation. Overexpression confers resistance to broad-spectrum cephalosporins including cefotaxime, ceftazidime, and ceftriaxone and is a problem especially in infections due to Enterobacter aerogenes and E. cloacae, where an isolate initially susceptible to these agents may become resistant upon therapy 7 . Transmissible plasmids have acquired genes for AmpC enzymes, which consequently can now appear in bacteria lacking or poorly expressing a chromosomal AmpC gene, such as Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. Resistance due to plasmid mediated AmpC enzymes is less common than ESBL production in most parts of the world but may be both harder to detect and broader in spectrum 7 .
Plasmid-mediated AmpC genes are of special interest because their mobility allows them to emerge in one genus or species and spread to different organisms. Combined disc diffusion test: The differences in inhibition zones for cefoxitin (30 µg) discs alone and in combination with (400 µg) of phenyl boronic acid was determined 4 . The zone diameters were similar and reproducible when the procedure was repeated. An increase of >5 mm in zone diameter in the presence of phenyl boronic acid compared with cefoxitin tested alone was considered to be positive for the presence of an AmpC β-lactamase production.
Molecular characterization of Ambler class C (AmpC)
resistance determinants: Multiplex PCR was used to detect the most common plasmid mediated AmpC genes ACC, FOX, MOX, DHA, CIT and EBC reported in literature using protocol previously reported 4, 15 . Preparation of template DNA -A single colony of each organism was inoculated from a Mac Conkey agar plate into 5 ml of nutrient broth (Becton Dickinson, Maryland, USA) and incubated for 16-18 h at 37°C. Cells from 1.5 ml of the overnight culture were harvested by centrifugation at 17,310 g for 5 min. After the supernatant was decanted, the pellet was resuspended in 500 µl of distilled water. The cells were lysed by heating at 95°C for 10 min, and cellular debris was removed by centrifugation at 17,310 g for 5 min. Supernatant (2 µl) was used as the DNA template source for amplification.
PCR was performed with a final volume of 25 μl in 0.2-ml thin-walled tubes. The primers used for PCR amplification are listed in Table I . Each reaction contained 20 mM Tris-HCl (pH 8.4); 50 mM KCl; 0.2 mM each deoxynucleoside triphosphate; 1.5 mM MgCl 2 ; 0.6 mM primers MOXMF, MOXMR, CITMF, CITMR, DHAMF, and DHAMR; 0.5 mM primers ACCMF, ACCMR, EBCMF, and EBCMR; 0.4 mM primers FOXMF and FOXMR 4 ; and 1.25 U of Taq DNA polymerase (Life Technologies, Rockville, USA). Template DNA (2 μl) was added to 23 μl of the master mixture. The PCR programme consisted of an initial denaturation step at 95°C for 2 min, followed by 30 cycles of DNA denaturation at 94°C for 45 sec, primer annealing at 62°C for 45 sec, and primer extension at 72°C for 1 min. After the last cycle, a final extension step at 72°C for 5 min was added. PCR product (15 μl) was analyzed by gel electrophoresis with 2 per cent agarose (USB Corporation, Cleveland, USA.). Gels were stained with ethidium bromide at 5 μg/ml and visualized by UV transillumination. A 100-bp DNA ladder (Fermentas International Inc. Burlington, Canada) was used as a molecular ladder. Negative controls were PCR mix with water in place of template DNA.
Control strains: Klebsiella pneumoniae ATCC 700603, Pseudomonas aeruginosa ATCC 27853, and E. coli ATCC 25922 were used to quality check the media, biochemical tests and susceptibility testing. ATCC standard strains were used to quality check E test and test ranges interpreted as per manufacturers, CLSI 2009 guidelines 14 . Amp C genotype standard strains A7 (ACC), A9 (CMY-2), and PMG252 (FOX-5) (provided by Dr George A Jacoby, Lahey Clinic, Burlington, Massachusetts, USA), and clinical isolate ADB05 (DHA), ADB42 (EBC) from our laboratory were used as PCR control strains.
Results
Overall, among 909 Gram-negative isolates, 312 were deemed cefoxitin resistant by Kirby Bauer disc diffusion test. This included E. coli (n=152), Klebsiella spp. (n=117) and Enterobacter spp. (n=43).
Among 312 cefoxitin resistant isolates, AmpC phenotype was confirmed by the combined disc diffusion testing in 36.5 per cent (n=114), in the remaining (n=198) it was not detectable. The overall occurrence of Amp C in the study was determined to be 12.5 per cent. Among the 312 cefoxitin resistant isolates, highest susceptibility to tigecycline (99%) was seen followed by imipenem, meropenem (97%), ertapenem (89%), amikacin (85%), and piperacillintazobactam (74.6%), resistance to levofloxacin was high (82%). There were no significant differences in susceptibility as well as MIC 50 and MIC 90 values (Table  II) among the AmpC producers (n=114) and Amp C negative isolates (n=198). A very high proportion (n=92%) of the AmpC phenotypes was also found to be ESBL producers with a significant number of them (n=81.7%) showing multidrug resistance.
Among 114 isolates of Amp C producers, 48 could be assigned a genotype, this included CIT-FOX (n=25), EBC (n=10), FOX (n = 4), CIT (n=3), and EBC-ACC (n=2), one each of DHA, EBC-DHA, FOX -DHA and FOX-EBC-DHA.
Isolates with plasmid mediated AmpC were recovered from patients with urinary tract (n=21), skin and soft tissue (n=17) and blood stream infection (n=10). Of these, 79.4 per cent were classified to be nosocomial in origin. The phenylboronic acid-cefoxitin disc tests showed corresponding sensitivity of 72.9 per cent, specificity of 45.4 per cent, positive predict value of 49.2 per cent, and negative predict value of 69.7 per cent when compared with PCR. Overall, presence of common plasmid mediated AmpC genotypes among Gram-negative isolates was low (5.2%). In our study, CIT-FOX (21.9%) and EBC Amp C (8.7%) genotypes were predominant. CIT-FOX like enzymes were common in E.coli (43.7%) and EBC like enzymes in K. pneumoniae (16.6%).
Discussion
The prevalence of plasmid AmpC-mediated resistance in India is not known, due to the limited number of surveillance studies seeking clinical strains producing AmpC β-lactamases and the difficulty that laboratories have in accurately detecting this resistance mechanism. The present study showed plasmid mediated AmpC β lactamases in 12.5 per cent isolates, with commonly reported genotypes seen among 5.2 per cent of them.
Plasmid AmpC β-lactamases have differential activity on β-lactamases inhibitors, E.coli derived enzymes have shown to exhibit resistance to inhibitor combinations with possible exception of piperacillintazobactam 1 . In previous Indian studies, cefoxitin resistant strains were tested for the production of AmpC β lactamases by three dimensional extract methods 16, 17 . A recent Indian study has recommended use of piperacillin and piperacillin-tazobactam discs for AmpC screening 18 . Cefotetan with phenyl boronic acid has also been used to detect AmpC especially MOX-1, FOX-1, ACT-1 producing isolates 19 . Detecting plasmid mediated AmpC with co-existing ESBL is very challenging. Given these difficulties in detecting plasmid mediated AmpC β-lactamases, their prevalence is currently being underestimated.
AmpC β-lactamases also have differential activity on substrates. E.coli with ACC−1 can be resistant to ceftazidime but not to cefotaxime or cefotetan while an isolate with DHA-2 may show intermediate resistance to cefoxitin but susceptible to cefotaxime or ceftazidime 1 . In our study, we could not discern such findings, further analysis of isolates including cephamycin hydrolysis assay is necessary to verify these effects.
In the study, sizeable number of cefoxitin resistant isolates were not positive for AmpC production by the disc potentiation test or PCR, this warrants further investigation into the other mechanisms of resistance and their laboratory detection. Clinical isolates rarely express more than one plasmid-mediated AmpC β-lactamases. Two reasons could explain this observation. First, the inability of current phenotypic tests to accurately detect the type of transferable AmpC β-lactamase does not allow for the differentiation of multiple AmpC enzymes. Second, it is possible that there is a limit to the amount of AmpC β-lactamase that a bacterial cell can accommodate and still be a viable pathogen 20 . A single type of test will not be able to accurately characterize the resistance mechanisms in these complex organisms. Although automated systems are available for susceptibility testing, the accuracy of these are inadequate for organisms expressing plasmidmediated AmpC β-lactamases alone or in combinations with ESBLs [21] [22] [23] . The use of cefoxitin resistance as a screening agent/ marker for AmpC production is quite reliable with a good negative predictive value as found in our study. The use of phenylboronic acid in combination with cefoxitin as a phenotypic screening method may be a better tool for laboratory diagnosis and confirmation of AmpC producing Gram-negative bacteria. The disc potentiation test reliably detected AmpC β-lactamase when compared against the PCR in the present study. Clinical laboratories interested in distinguishing AmpC mediated resistance from other β-lactamase resistance mechanisms will need to use combination of phenotypic and molecular identification methods. The multiplex PCR technique described in this study will be an important tool for the detection of plasmidmediated AmpC β-lactamases genes in Gram-negative bacteria.
In the present study, MDR among AmpC positive study isolates was high suggesting plasmid mediated spread. Current therapeutic options include use of cefepime or carbapenems 7 , however, the high cocarriage of ESBL and AmpC in this study and the fact that majority of these were nosocomial in origin is a cause for concern. This study findings indicate the necessity for continued surveillance of mechanisms of resistance among nosocomial pathogens and evolving preventive measures aimed at reducing their spread.
